Business Wire

Eaton’s Vehicle Group and eMobility Continue to Expand Footprint in Europe to Support Growth of Electrified Vehicle Market

26.4.2022 13:30:00 EEST | Business Wire | Press release

Share

Power management company Eaton today announced its Vehicle Group and eMobility businesses are continuing their expansion into Europe, a leading region in electrified vehicle (EV) technology, with the establishment of a new office and research center in Karlsruhe, Germany. This expansion will complement existing engineering and manufacturing sites in Montrottier, France, and Tczew, Poland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005305/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton eMobility engineer inspects a high-voltage traction inverter for electric vehicles. (Photo: Business Wire)

The new office in Karlsruhe will serve as a base for customer interaction and engineering service for Eaton’s Vehicle Group and eMobility customers in the region. The facility will include a new laboratory that enables rapid turnaround in testing Eaton’s latest eMobility products.

“The city of Karlsruhe is a central location in Europe near major automotive manufacturers and suppliers, allowing us to be closer to our customers and satisfy their needs in terms of research and development,” said Scott Adams, president, eMobility, Eaton. “The new facility is also close to several prestigious universities, which will allow us to attract talent for our research center.’’

This location will also host Vehicle Group employees from varying product lines and functions, ensuring an integrated approach and alignment with customers across the region.

Eaton is also expanding and upgrading its engineering and manufacturing capacity across its other sites in the region.

The Vehicle Group’s recent expansion of its Tczew facility includes investing more than $20 million (USD) to add an innovative laboratory and three new automated production lines to manufacture EV components for its eMobility customers.

Equipment for the new eMobility lines is currently being installed, with the start of production scheduled for the first quarter of 2023. The lines will initially produce traction inverters for a major European automaker that will save energy and help increase the range of EVs and contribute to extended battery life. Additional eMobility solutions will later be produced at the plant, including power distribution units.

In addition, Eaton’s eMobility location in Montrottier is undergoing expansion to support the demand for power electronics and power distribution products for EVs in the automotive sector. Due to its location, the Montrottier plant serves both European-based vehicle manufacturers and suppliers, as well as global customers.

Three new assembly lines will increase output at the facility up to four times that of current levels, and a new cleanroom will allow for testing in a sterile environment. Eaton also will be adding engineering, manufacturing, and support staff to sustain increased production.

“Eaton’s continued expansion in Europe is a crucial step to growing the traditional Vehicle and eMobility businesses and offering cutting-edge EV solutions to our global customers across the region,” said Marco Martini, president, Vehicle Group, Europe, Middle East and Africa (EMEA), Eaton. “These upgrades will support Eaton’s efforts in delivering electric vehicle solutions to passenger car, commercial vehicle and off-highway OEMs globally.”

Eaton’s Vehicle Group and eMobility businesses continue to seek talent for growing global teams. Learn more about opportunities with Eaton’s eMobility.

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.

Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye